# A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

> **NCT04497987** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1180 (actual)

## Conditions studied

- COVID-19
- SARS-CoV2

## Interventions

- **DRUG:** Bamlanivimab
- **DRUG:** Placebo
- **DRUG:** Etesevimab

## Key facts

- **NCT ID:** NCT04497987
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-02
- **Primary completion:** 2021-01-16
- **Final completion:** 2021-05-20
- **Target enrollment:** 1180 (ACTUAL)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04497987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04497987, "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04497987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*